These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31692115)

  • 21. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
    Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
    N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
    Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
    J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.
    Adam FC; Szybinski J; Halter JP; Cantoni N; Wenzel F; Leonards K; Brkic S; Passweg JR; Touw I; Maxson JE; Meyer SC
    Curr Oncol; 2022 Feb; 29(2):805-815. PubMed ID: 35200567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
    Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
    Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
    Yin B; Chen X; Gao F; Li J; Wang HW
    Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
    [No Abstract]   [Full Text] [Related]  

  • 29. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT.
    Langabeer SE; McCarron SL; Haslam K; O'Donovan MT; Conneally E
    Bone Marrow Transplant; 2014 Jun; 49(6):843-4. PubMed ID: 24614839
    [No Abstract]   [Full Text] [Related]  

  • 31. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia.
    Faisal M; Stark H; Büsche G; Schlue J; Teiken K; Kreipe HH; Lehmann U; Bartels S
    Cancer Med; 2019 Feb; 8(2):742-750. PubMed ID: 30635983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-Sensitive
    Klimiankou M; Uenalan M; Kandabarau S; Nustede R; Steiert I; Mellor-Heineke S; Zeidler C; Skokowa J; Welte K
    Front Immunol; 2019; 10():116. PubMed ID: 30891028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical Chronic Myeloid Leukemia: Where Are We Now?
    Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical chronic myeloid leukemia: a rare entity with management challenges.
    Dhakal P; Gundabolu K; Amador C; Rayamajhi S; Bhatt VR
    Future Oncol; 2018 Jan; 14(2):177-185. PubMed ID: 29226717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of
    Cui M; Li QY; Lu XZ; Chao HY; Cai XH; Liu J; Hua HY; Wu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1019-1025. PubMed ID: 37551471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
    Tefferi A; Elliott M; Pardanani A
    Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
    Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
    Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
    Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
    Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
    Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.